206 related articles for article (PubMed ID: 15046712)
1. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
[TBL] [Abstract][Full Text] [Related]
3. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM
Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565
[TBL] [Abstract][Full Text] [Related]
4. Molecular staging by RT-pCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer.
Mitsiades CS; Lembessis P; Sourla A; Milathianakis C; Tsintavis A; Koutsilieris M
Clin Exp Metastasis; 2004; 21(6):495-505. PubMed ID: 15679047
[TBL] [Abstract][Full Text] [Related]
5. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer.
Olsson CA; De Vries GM; Benson MC; Raffo A; Buttyan R; Cama C; O'Toole K; Katz AE
Br J Urol; 1996 Mar; 77(3):411-7. PubMed ID: 8814848
[TBL] [Abstract][Full Text] [Related]
6. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
[TBL] [Abstract][Full Text] [Related]
7. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival.
Wood DP; Banerjee M
J Clin Oncol; 1997 Dec; 15(12):3451-7. PubMed ID: 9396397
[TBL] [Abstract][Full Text] [Related]
8. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes: comparison with standard histological staging and immunohistochemical assessment of occult regional lymph node metastases.
Martínez-Piñeiro L; Rios E; Martínez-Gomariz M; Pastor T; de Cabo M; Picazo ML; Palacios J; Perona R
Eur Urol; 2003 Apr; 43(4):342-50. PubMed ID: 12667714
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract][Full Text] [Related]
10. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
11. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay.
Katz AE; Olsson CA; Raffo AJ; Cama C; Perlman H; Seaman E; O'Toole KM; McMahon D; Benson MC; Buttyan R
Urology; 1994 Jun; 43(6):765-75. PubMed ID: 7515202
[TBL] [Abstract][Full Text] [Related]
12. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
13. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
[TBL] [Abstract][Full Text] [Related]
14. [RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients].
Okubo Y; Ito T
Hinyokika Kiyo; 1999 Jan; 45(1):25-30. PubMed ID: 10086262
[TBL] [Abstract][Full Text] [Related]
15. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer.
Ellis WJ; Vessella RL; Corey E; Arfman EW; Oswin MM; Melchior S; Lange PH
J Urol; 1998 Apr; 159(4):1134-8. PubMed ID: 9507816
[TBL] [Abstract][Full Text] [Related]
16. Detecting circulating prostate cells in patients with clinically localized prostate cancer: clinical implications for molecular staging.
Llanes L; Páez A; Ferruelo A; Luján M; Romero I; Berenguer A
BJU Int; 2000 Dec; 86(9):1023-7. PubMed ID: 11119095
[TBL] [Abstract][Full Text] [Related]
17. Quantitative real-time reverse transcription: polymerase chain reaction of prostate-specific antigen (PSA) for detection of circulating prostatic cells in patients with clinically localized prostate cancer.
Llanes L; Ferruelo A; Luján M; Pascual C; García-Mediero JM; Berenguer A
Prostate Cancer Prostatic Dis; 2005; 8(3):248-52. PubMed ID: 15897916
[TBL] [Abstract][Full Text] [Related]
18. Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.
Gao CL; Maheshwari S; Dean RC; Tatum L; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
Urology; 1999 Apr; 53(4):714-21. PubMed ID: 10197846
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.
Kurek R; Nunez G; Tselis N; Konrad L; Martin T; Roeddiger S; Aumüller G; Zamboglou N; Lin DW; Tunn UW; Renneberg H
Clin Cancer Res; 2004 Sep; 10(17):5808-14. PubMed ID: 15355910
[TBL] [Abstract][Full Text] [Related]
20. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
